These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 26893577)

  • 1. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide.
    Cernaro V; Santoro D; Lacquaniti A; Costantino G; Visconti L; Buemi A; Buemi M
    Int J Nephrol Renovasc Dis; 2016; 9():11-9. PubMed ID: 26893577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
    Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
    Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.
    Cozzolino M; Funk F; Rakov V; Phan O; Teitelbaum I
    Curr Drug Metab; 2014; 15(10):953-65. PubMed ID: 25658128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
    Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
    Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
    Phan O; Maillard M; Malluche HH; Stehle JC; Funk F; Burnier M
    Biomed Res Int; 2015; 2015():515606. PubMed ID: 26221597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
    Coyne DW; Sprague SM; Vervloet M; Ramos R; Kalantar-Zadeh K
    J Nephrol; 2022 Apr; 35(3):875-888. PubMed ID: 35138627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
    Bousher A; Al-Makki A; Sutton J; Shepler B
    Clin Ther; 2014 Dec; 36(12):2082-2093. PubMed ID: 25450474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
    Floege J; Covic AC; Ketteler M; Mann J; Rastogi A; Spinowitz B; Rakov V; Lisk LJ; Sprague SM
    Nephrol Dial Transplant; 2017 Nov; 32(11):1918-1926. PubMed ID: 28339993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
    Ketteler M; Sprague SM; Covic AC; Rastogi A; Spinowitz B; Rakov V; Walpen S; Floege J
    Nephrol Dial Transplant; 2019 Jul; 34(7):1163-1170. PubMed ID: 29846719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?
    Negri AL; Ureña Torres PA
    Clin Kidney J; 2015 Apr; 8(2):161-7. PubMed ID: 25815172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
    Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
    Greig SL; Plosker GL
    Drugs; 2015 Apr; 75(5):533-42. PubMed ID: 25761962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
    Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
    PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study.
    Yaguchi A; Akahane K; Tsuchioka K; Yonekubo S; Yamamoto S; Tamai Y; Tatemichi S; Takeda H
    BMC Nephrol; 2019 Dec; 20(1):465. PubMed ID: 31830936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Sprague SM; Floege J
    Expert Opin Pharmacother; 2018 Jul; 19(10):1137-1148. PubMed ID: 29985725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Sprague SM; Ketteler M
    Expert Opin Drug Saf; 2021 Dec; 20(12):1463-1472. PubMed ID: 34511018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients.
    Koiwa F; Yokoyama K; Fukagawa M; Akizawa T
    Kidney Int Rep; 2018 Jan; 3(1):185-192. PubMed ID: 29340330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease.
    Cernaro V; Calimeri S; Laudani A; Santoro D
    Ther Clin Risk Manag; 2020; 16():871-880. PubMed ID: 32982259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.